Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
TBPH | NASDAQ | USD | Real-time | |
0TB | TradeGate | EUR | Delayed | |
0TB | Frankfurt | EUR | Delayed |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Rick E. Winningham | 64 | 2013 | Chairman & CEO |
Eran Broshy | 65 | 2014 | Independent Director |
Laurie Smaldone Alsup | 70 | 2018 | Independent Director |
Susannah Gray | 63 | 2023 | Independent Director |
James C. Kelly | - | 2023 | Independent Director |
Jeremy T. Grant | 36 | 2023 | Independent Director |
Dean Jonathan Mitchell | 68 | 2014 | Lead Independent Director |
Donal M. O'Connor | 73 | 2015 | Independent Director |
Deepika Rachel Pakianathan | 59 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review